Overexpression of Metallothionein Reduces Diabetic Cardiomyopathy
Overexpression of Metallothionein Reduces Diabetic Cardiomyopathy Qiangrong Liang 1 , Edward C. Carlson 2 , Rajakumar V. Donthi 3 , Patrica M. Kralik 3 , Xia Shen 3 and Paul N. Epstein 3 1 Division of Molecular Cardiovascular Biology, University of Cincinnati, Ohio 2 Department of Anatomy and Cell B...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 51; no. 1; pp. 174 - 181 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Diabetes Association
01.01.2002
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Overexpression of Metallothionein Reduces Diabetic Cardiomyopathy
Qiangrong Liang 1 ,
Edward C. Carlson 2 ,
Rajakumar V. Donthi 3 ,
Patrica M. Kralik 3 ,
Xia Shen 3 and
Paul N. Epstein 3
1 Division of Molecular Cardiovascular Biology, University of Cincinnati, Ohio
2 Department of Anatomy and Cell Biology, University of North Dakota, Grand Forks, North Dakota
3 Department of Pediatrics, University of Louisville, Louisville, Kentucky
Abstract
Many diabetic patients suffer from cardiomyopathy, even in the absence of vascular disease. This diabetic cardiomyopathy predisposes
patients to heart failure and mortality from myocardial infarction. Evidence from animal models suggests that reactive oxygen
species play an important role in the development of diabetic cardiomyopathy. Our laboratory previously developed a transgenic
mouse model with targeted overexpression of the antioxidant protein metallothionein (MT) in the heart. In this study we used
MT-transgenic mice to test whether an antioxidant protein can reduce cardiomyopathy in the OVE26 transgenic model of diabetes.
OVE26 diabetic mice exhibited cardiomyopathy characterized by significantly altered mRNA expression, clear morphological abnormalities,
and reduced contractility under ischemic conditions. Diabetic hearts appeared to be under oxidative stress because they had
significantly elevated oxidized glutathione (GSSG). Diabetic mice with elevated cardiac MT (called OVE26MT mice) were obtained
by crossing OVE26 transgenic mice with MT transgenic mice. Hyperglycemia in OVE26MT mice was indistinguishable from hyperglycemia
in OVE26 mice. Despite this, the MT transgene significantly reduced cardiomyopathy in diabetic mice: OVE26MT hearts showed
more normal levels of mRNA and GSSG. Typically, OVE26MT hearts were found to be morphologically normal, and elevated MT improved
the impaired ischemic contractility seen in diabetic hearts. These results demonstrate that cardiomyocyte-specific expression
of an antioxidant protein reduces damage to the diabetic heart.
Footnotes
Address correspondence and reprint requests to Paul N. Epstein, Department of Pediatrics, University of Louisville, Baxter
Research Building, Suite 321, Louisville, KY 40202. E-mail: paul.epstein{at}louisville.edu .
Received for publication 23 March 2001 and accepted in revised form 19 October 2001.
ANF, atrial natriuretic factor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSH, glutathione; GSSG, oxidized GSH; M2VP,
1-methyl-2-vinyl-pyridinium trifluoromethane sulfonate; MT, metallothionein; ROS, reactive oxygen species. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/diabetes.51.1.174 |